UAE accelerates advanced diagnostics adoption ahead of WHX 2027
The United Arab Emirates is positioning itself as the Middle East's most advanced diagnostics market, according to a Frost & Sullivan analysis commissioned for the World Health Expo (WHX). The report, released ahead of the January 2027 trade event in Dubai, projects the global clinical diagnostics market will grow from $115.7 billion in 2026 to $152.1 billion by 2031, a compound annual growth rate of 5.5%.
The UAE's approach, the report argues, is distinguished not merely by technology procurement but by the parallel development of genomics infrastructure, integrated laboratory networks, AI-enabled diagnostic tools, and reimbursement frameworks. The authors contend that building these capabilities simultaneously, rather than sequentially, is accelerating the transition of new tests from development into routine clinical use.
Genomics and molecular diagnostics in focus
Among the specific developments cited, the UAE Genome Programme is constructing population-level genomic databases to underpin personalised healthcare and research. Cleveland Clinic Abu Dhabi is offering precision oncology services, next-generation sequencing, and hereditary cancer screening. Since January 2025, genetic screening covering 570 genes linked to more than 840 hereditary conditions has been mandatory for UAE nationals as part of pre-marital health checks.
The molecular diagnostics segment is highlighted as a primary beneficiary of this structural shift. Frost & Sullivan forecasts that segment will grow globally from $26.9 billion in 2026 to $36 billion by 2031, driven by advances in tumour molecular profiling, companion diagnostics, and infectious disease monitoring. The report notes that reimbursement for next-generation sequencing in oncology and companion diagnostics is already established in the UAE.
On the laboratory infrastructure side, Pure Lab, the integrated network operated by Pure Health and described as the largest of its kind in the country, processed 34 million tests in 2025, a 17% year-on-year increase from 29 million in 2024.
Market context and trade-show framing
Mohini Mehta, a senior consultant at Frost & Sullivan, said the UAE was "developing these capabilities in parallel rather than building them one at a time," and suggested that by 2031, markets taking this approach would accumulate real-world evidence on what works and what the genuine cost of delivering advanced diagnostics at scale looks like.
It is worth noting that the report was commissioned by Informa Markets, the organiser of WHX, as a marketing asset for the event's dedicated laboratory zone. WHX 2027 is scheduled for 25-28 January in Dubai, targeting more than 90,000 attendees and 4,200 exhibitors from 195 countries. The laboratory zone will include conference sessions covering molecular diagnostics, genomics, digital pathology, and AI applications, with speakers drawn from UAE institutions including M42's National Reference Laboratory, Pure Lab, Dubai Health, and the Emirates Society for Clinical Chemistry.
The broader Middle East clinical diagnostics market is valued at approximately $5.4 billion in 2026. Point-of-care testing is a globally significant growth driver within that: Frost & Sullivan forecasts rapid diagnostics growing from $19.1 billion in 2026 to $26.2 billion by 2031, at a 6.4% CAGR, as rapid testing platforms expand into urgent care and community settings beyond traditional laboratories.
Diagnostics suppliers seeking access to Gulf procurement decision-makers will find this context useful. GCC hospital groups and integrated primary care networks are increasingly consolidating purchasing, with system connectivity, remote quality monitoring, and laboratory information system integration now standard tender requirements across the region.